Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial

The natural history of patients with newly diagnosed high-risk nonmetastatic (M0) prostate cancer receiving hormone therapy (HT) either alone or with standard-of-care radiotherapy (RT) is not well documented. Furthermore, no clinical trial has assessed the role of RT in patients with node-positive (...

Full description

Bibliographic Details

Published in:	JAMA oncology Vol. 2; no. 3; pp. 348 - 357
Main Authors:	James, Nicholas D, Spears, Melissa R, Clarke, Noel W, Dearnaley, David P, Mason, Malcolm D, Parker, Christopher C, Ritchie, Alastair W S, Russell, J Martin, Schiavone, Francesca, Attard, Gerhardt, de Bono, Johann S, Birtle, Alison, Engeler, Daniel S, Elliott, Tony, Matheson, David, O'Sullivan, Joe, Pudney, Delia, Srihari, Narayanan, Wallace, Jan, Barber, Jim, Syndikus, Isabel, Parmar, Mahesh K B, Sydes, Matthew R
Format:	Journal Article
Language:	English
Published:	United States 01.03.2016
Subjects:	Aged Dose Fractionation, Radiation Humans Kallikreins - blood Male Middle Aged Prostate-Specific Antigen - blood Prostatic Neoplasms - mortality Prostatic Neoplasms - pathology Prostatic Neoplasms - radiotherapy Radiotherapy - adverse effects Radiotherapy - methods Survival Analysis Treatment Outcome
ISSN:	2374-2445
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!